# Can AI Diagnostic Pathways Cut Respiratory Care Costs?

Lily Armstrong · October 11, 2026

> AI Guides Cost-Effective Breathlessness Diagnosis Chronic breathlessness is one of the most common and expensive reasons patients enter the healthcare...

## AI Guides Cost-Effective Breathlessness Diagnosis

Chronic breathlessness is one of the most common and expensive reasons patients enter the healthcare system, yet the diagnostic journey often involves redundant imaging, specialist referrals, and lengthy delays. A recent study published in Nature suggests artificial intelligence could change that. By analyzing patient data to determine the optimal sequence of tests, AI-guided diagnostic pathways can identify which patients need advanced imaging, which need pulmonary function testing, and which can be safely monitored, reducing unnecessary procedures while maintaining diagnostic accuracy. Researchers found that this approach not only shortens the time to diagnosis but also delivers meaningful cost savings by avoiding low-value care.

**Also worth reading:** [How Can an AI Healthcare Benefits Consultant Cut Costs and Improve Care?](https://healtho.io/knowledge/how_can_an_ai_healthcare_benefits_consultant_cut_costs_and_improve_care.php) · [What Are the Most Effective COPD Cessation Medications and Treatment Pathways?](https://healtho.io/knowledge/what_are_the_most_effective_copd_cessation_medications_and_treatment_pathways.php) · [What's the Right Creatine Dosing for Women Over 40?](https://healtho.io/knowledge/whats_the_right_creatine_dosing_for_women_over_40.php)

The economics look equally compelling in related respiratory applications. A Vanderbilt study demonstrated that an AI-assisted risk model for lung nodules is cost-effective, and Optellum's lung nodule risk stratification platform showed strong cost-effectiveness in the first US lifetime payer analysis, supporting broader adoption by health systems and insurers. As hospitals face pressure from shifting payer mixes and tighter margins, tools that streamline respiratory workups offer a practical path to better outcomes at lower cost. For providers evaluating AI investments, breathlessness and lung nodule pathways represent some of the clearest near-term returns.

## Lung Nodule Risk Models Save Payer Dollars

Chronic breathlessness is one of the most expensive diagnostic puzzles in respiratory care, often triggering cascades of imaging, pulmonary function testing, and specialist referrals before a diagnosis is reached. A recent Nature study suggests artificial intelligence can change that trajectory by identifying the most cost-effective diagnostic pathways for individual patients. Rather than applying a one-size-fits-all workup, AI models weigh pre-test probability, comorbidities, and imaging findings to recommend the sequence of tests most likely to yield answers quickly. For payers, the appeal is straightforward: fewer redundant tests, shorter time to diagnosis, and lower total cost of care without compromising quality.

The economics are especially compelling in lung nodule management. Vanderbilt researchers and a first-of-its-kind US lifetime payer study of Optellum's AI platform both found that AI-assisted risk stratification of pulmonary nodules is cost-effective, helping clinicians decide which nodules warrant aggressive follow-up and which can be safely monitored. By reducing unnecessary biopsies and surveillance CTs while catching malignant nodules earlier, these models shift spending from wasteful diagnostics toward timely intervention. As HCA's recent earnings discussion of shifting payer mix underscores, health systems face mounting pressure to demonstrate value. AI-guided diagnostic pathways offer a concrete way to do exactly that.

## Optellum Study Proves Lifetime Cost Savings

A lifetime payer study published in the US has demonstrated that Optellum's AI-based lung nodule risk stratification is highly cost-effective, offering a compelling answer to a question health systems are increasingly asking: can AI diagnostic pathways actually cut respiratory care costs? The study, the first of its kind in the US to model lifetime costs, suggests that using AI to determine which lung nodules warrant aggressive follow-up versus watchful waiting can save payers substantial money over a patient's lifetime while improving clinical outcomes. This aligns with broader research, including a Nature-published study showing AI can identify optimal, cost-effective diagnostic pathways for patients with chronic breathlessness, a symptom that often triggers expensive, repetitive testing.

The findings arrive at a moment when hospital systems like HCA are navigating lower seasonal volumes and shifting payer mixes, putting pressure on margins and making efficiency gains more valuable. Vanderbilt research similarly supports AI-assisted risk models for lung nodules as cost-effective. For respiratory care, where diagnostic uncertainty drives unnecessary CT scans, biopsies, and specialist referrals, AI-guided triage represents one of the clearest near-term opportunities to reduce waste without compromising care quality.

## Sleep Apnea Monitoring Cuts ICU Transfers

AI diagnostic pathways can meaningfully reduce respiratory care costs by triaging chronic breathlessness earlier and more accurately. Research published in Nature demonstrates that AI-guided determination of optimal cost-effective diagnostic pathways for chronic breathlessness helps clinicians avoid unnecessary testing while catching treatable disease sooner. Earlier, precise diagnosis means fewer emergency escalations, shorter hospital stays, and less intensive resource use across the care continuum.

Lung nodule risk stratification offers the clearest financial evidence. A Vanderbilt Health study found AI-assisted risk models for lung nodules cost-effective, and the first US lifetime payer study of Optellum's AI platform showed strong cost-effectiveness for nodule risk stratification. By guiding surveillance versus intervention, these tools reduce low-value follow-up imaging and invasive procedures. For payers and providers alike, AI diagnostic pathways are emerging as a practical lever for bending the respiratory care cost curve without compromising outcomes.

## Pembrolizumab Delivery Costs Under AI Scrutiny

Health systems are increasingly turning to artificial intelligence to determine the most cost-effective diagnostic pathways for patients with chronic breathlessness, according to research published in Nature. The study suggests AI-driven decision support can help clinicians select imaging and testing sequences that reduce unnecessary procedures while maintaining diagnostic accuracy. In parallel, Vanderbilt researchers report that an AI-assisted risk model for evaluating lung nodules is cost-effective, and a first-of-its-kind US lifetime payer study found Optellum's AI lung nodule risk stratification tool delivers economic value for payers. Together, these findings point toward AI as a mechanism for trimming respiratory care costs at the diagnostic stage, where overuse of CT scans and specialist referrals drives significant spending.

The cost conversation extends to treatment delivery as well. Subcutaneous pembrolizumab, marketed as a convenience-driven alternative to intravenous infusion, is facing scrutiny over its actual convenience and cost impact for cancer patients, as reported by OncLive. Meanwhile, HCA Healthcare's first-quarter results revealed lower seasonal volumes and a shifting payer mix weighing on performance, underscoring the financial pressure providers face. As margins tighten, the appeal of AI tools that demonstrably reduce diagnostic spending grows stronger, positioning respiratory care as an early proving ground for value-based AI adoption across healtho.io's coverage of AI healthcare economics.

## AI Respiratory Savings Comparison

Can AI Diagnostic Pathways Cut Respiratory Care Costs?

| Study / Source | AI Application | Cost Impact |
| --- | --- | --- |
| Nature | AI-guided diagnostic pathways for chronic breathlessness | Optimizes test selection, reducing redundant workups and accelerating diagnosis |
| Vanderbilt Health News | AI-assisted risk model for lung nodules | Cost-effective triage, limiting unnecessary invasive biopsies and follow-up imaging |
| PR Newswire (Optellum AI) | Lung nodule risk stratification | Demonstrated highly cost-effective in first US lifetime payer study |
| healtho.io Consulting | AI Healthcare Benefits Consulting | Translates respiratory AI evidence into payer-aligned, savings-driven benefits strategy |

AI diagnostic pathways are proving their value in respiratory care. From chronic breathlessness workups to lung nodule risk stratification, studies show AI-guided triage reduces unnecessary testing, shortens time to diagnosis, and lowers payer costs. For health plans and providers, the message is clear: smarter, AI-assisted respiratory pathways deliver measurable savings without compromising care quality. healtho.io helps organizations translate these findings into benefits strategy.

## Quick answers

### How does AI reduce costs in chronic breathlessness care?

AI steers clinicians toward the least invasive, highest-yield tests first, avoiding unnecessary procedures and repeat visits.

### What did the Optellum payer study find?

Optellum's AI safely triaged low-risk lung nodules, cutting follow-up scans and invasive biopsies across a lifetime of care.

### Can continuous monitoring lower respiratory expenses?

Masimo SET-based monitoring reduced distress codes and ICU transfers, generating measurable savings in monitored patients.

### Are AI savings limited to lung conditions?

No, AI tools like EcoRxAgent also target pharmacy spending, and treating sleep apnea prevents billions in added medical costs.

Canonical: https://healtho.io/knowledge/can_ai_diagnostic_pathways_cut_respiratory_care_costs.php
Markdown: https://healtho.io/knowledge/can_ai_diagnostic_pathways_cut_respiratory_care_costs.php/index.md